What is the 13F Pro Quality Score for MXCT?

13F Pro ranks MAXCYTE, INC. (MXCT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MXCT's current score at https://13fpro.ai/research/MXCT (free sign-up required for the full ranking).

Which hedge funds own the most MXCT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MXCT include BlackRock,, Capricorn Fund Managers Ltd, Vitruvian Partners LLP. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MXCT as soon as new 13F filings post.

Where does 13F Pro source MXCT data?

All MAXCYTE, INC. fundamentals and ownership data come directly from SEC EDGAR. MAXCYTE, INC. files with the SEC under CIK 1287098. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MXCT in?

MAXCYTE, INC. (MXCT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MXCT research updated on 13F Pro?

MXCT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MAXCYTE, INC.(MXCT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1287098 MXCT stock profile & AI dashboard →

13F Pro Quality Score

16.7/100

Rank #2,730 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

35.3/100

Profitability

5.6/100

Balance Sheet

11.8/100

Earnings Quality

30.0/100

Free Cash Flow

5.0/100

Institutional Flow

66.9/100

Revenue Scale

5.5/100

Dilution Risk

6.8/100

MXCT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MAXCYTE, INC. (MXCT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MXCT at 16.7/100 on a 32-signal composite quality model, placing it at rank #2,730 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (5.0) and revenue scale (5.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), MAXCYTE, INC. reports quarterly revenue of $9.7M, net income of $-4.8M, free cash flow of $-8.2M. Top institutional holders of MXCT by reported 13-F value include BlackRock,, Capricorn Fund Managers Ltd, Vitruvian Partners LLP, based on the most recent SEC filings. MXCT trades on the Nasdaq exchange and files with the SEC under CIK 1287098. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MXCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MAXCYTE, INC. directly from SEC EDGAR. MAXCYTE, INC.'s 13F Pro composite quality score has ranged between 13 and 35 since 2022, currently 16.7 — a declining long-term trajectory across 24 quarterly and live scoring snapshots.

✦

Fun facts about MAXCYTE, INC.

Quirks, history, and lore behind MXCT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. life sciences tools company · small-cap · listed on Nasdaq · headquartered in Maryland.
2
The Numbers
Annual revenue in the range of tens of millions of dollars, with the company still in growth/investment mode — profitability is a work in progress, not the current headline.
3
The History
Founded in the early 2000s, it spent years as a private company quietly building a platform before going public and planting its flag firmly in the cell therapy revolution.
4
The Secret
It doesn't make drugs itself — it sells the electroporation technology that lets other companies engineer living cells into potential medicines, acting as the picks-and-shovels supplier to the industry.
5
The Lore
Its Flow Electroporation platform can process billions of cells at once, which is exactly the kind of scalability that CAR-T and gene therapy developers dream about.
6
The Giveaway
If a major biotech is editing or loading up immune cells for a next-gen therapy, there's a good chance this Gaithersburg, Maryland company's instruments are in the room — ticker starts with MX.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$9.7M

Net Income

Q1 2026

$-4.8M

Free Cash Flow

Q1 2026

$-8.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-14.5% YoY

$33.0MFY 2025

FY22 $44.3MFY23 $41.3MFY24 $38.6MFY25 $33.0M

Net Income

-8.7% YoY

$-44.6MFY 2025

FY22 $-23.6MFY23 $-37.9MFY24 $-41.1MFY25 $-44.6M

Operating Income

-1.4% YoY

$-51.9MFY 2025

FY22 $-27.4MFY23 $-48.3MFY24 $-51.2MFY25 $-51.9M

EPS (Diluted)

-7.7% YoY

$-0.42FY 2025

FY22 $-0.23FY23 $-0.37FY24 $-0.39FY25 $-0.42

Total Assets

-15.4% YoY

$202.5MFY 2025

FY22 $286.7MFY23 $268.3MFY24 $239.5MFY25 $202.5M

Op. Cash Flow

-24.6% YoY

$-34.4MFY 2025

FY22 $-14.8MFY23 $-21.7MFY24 $-27.6MFY25 $-34.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$33.0M -14.5%	$38.6M -6.4%	$41.3M -6.7%	$44.3M +30.6%	$33.9M +29.5%	$26.2M
Net Income	$-44.6M -8.7%	$-41.1M -8.3%	$-37.9M -60.9%	$-23.6M -23.5%	$-19.1M -61.5%	$-11.8M
Operating Income	$-51.9M -1.4%	$-51.2M -6.0%	$-48.3M -76.5%	$-27.4M -50.4%	$-18.2M -64.5%	$-11.1M
EPS (Diluted)	$-0.42 -7.7%	$-0.39 -5.4%	$-0.37 -60.9%	$-0.23 -9.5%	$-0.21 -23.5%	$-0.17
Total Assets	$202.5M -15.4%	$239.5M -10.7%	$268.3M -6.4%	$286.7M +0.9%	$284.1M +448.7%	$51.8M
Operating Cash Flow	$-34.4M -24.6%	$-27.6M -27.3%	$-21.7M -46.7%	$-14.8M -38.4%	$-10.7M -21.6%	$-8.8M

AI Insight: MXCT Financial Trends

MXCT remains deeply unprofitable with deteriorating revenue and shareholder equity, though losses narrowed in Q1 2026.

• Revenue collapsed 30% from $10M in Q2 2024 to $7M in Q3 2025, recovering only to $10M in Q1 2026.

• Net loss improved to $5M in Q1 2026 from $12M in Q2–Q3 2025, but sustained cash burn and negative operating cash flow persist.

• Equity eroded 24% from $221M in Q2 2024 to $168M in Q1 2026, reflecting cumulative losses and no debt financing.

⚠ Operating cash burn worsened to $14M in Q1 2025 before improving to $3M in Q4 2025; sustainability unclear at current burn rates.

⚠ Revenue volatility ($7M–$10M range) and no clear growth trajectory suggest execution or demand challenges.

AI Insight: MXCT Ratio Trends

Operating margin improved sharply to -64.1% in Q1 2026, marking the best quarter in nearly two years, though company remains deeply unprofitable.

• Operating margin improved 89.7pp from Q3 2025 to -64.1% in Q1 2026, best result since Q2 2024 (-114.8%).

• ROE, ROA, and ROIC all improved substantially in Q1 2026: ROE to -11.3% from -22.4% prior quarter.

• Net profit margin at -49.2% in Q1 2026, narrowest loss since Q1 2025 (-98.8%), signaling operational progress.

⚠ Company remains unprofitable across all metrics; Q1 2026 improvement may not sustain given Q3 2025 deterioration.

⚠ Q3 2025 showed sharp NPM deterioration to -181.8% and ROIC to -31.4%, indicating execution volatility.

⚠ TTM ROIC of -27.3% reflects persistent negative returns on invested capital despite recent quarter progress.

Get alerted when MXCT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MAXCYTE, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MXCT

BlackRock, Inc.
$6.2M8,798,473 sh
Capricorn Fund Managers Ltd
$5.8M8,200,000 sh
Vitruvian Partners LLP
$3.5M5,043,356 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.8M3,981,816 sh
MORGAN STANLEY
$2.6M3,688,131 sh
Mudita Advisors LLP
$2.4M3,370,689 sh
BNP Paribas Asset Management Holding S.A.
$1.9M2,773,554 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.7M2,362,672 sh
STATE STREET CORP
$1.5M2,193,470 sh
Brooklands Fund Management Ltd
$1.5M2,190,020 sh

Fund	Value	Shares
BlackRock, Inc.	$6.2M	8,798,473
Capricorn Fund Managers Ltd	$5.8M	8,200,000
Vitruvian Partners LLP	$3.5M	5,043,356
VANGUARD CAPITAL MANAGEMENT LLC	$2.8M	3,981,816
MORGAN STANLEY	$2.6M	3,688,131
Mudita Advisors LLP	$2.4M	3,370,689
BNP Paribas Asset Management Holding S.A.	$1.9M	2,773,554
GEODE CAPITAL MANAGEMENT, LLC	$1.7M	2,362,672
STATE STREET CORP	$1.5M	2,193,470
Brooklands Fund Management Ltd	$1.5M	2,190,020

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MXCT on your watchlist

Track score changes the day MAXCYTE, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MXCT a good stock to buy?

13F Pro's AI-powered analysis of MAXCYTE, INC. (MXCT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MXCT are available on the MXCT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MXCT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MXCT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MAXCYTE, INC.'s investment landscape.